More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$673844877
EPS
0.16
P/E ratio
1536
Price to sales
5.59
Dividend yield
--
Beta
0.614593
Previous close
$19.87
Today's open
$19.90
Day's range
$19.33 - $20.01
52 week range
$8.12 - $22.51
show more
CEO
Gerard Michel
Employees
156
Headquarters
Queensbury, NY
Exchange
NASDAQ Capital Market
Shares outstanding
34788068
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose grant date was in either September 2026 or October 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 21,2.
Business Wire • 19 hours ago

Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks Investment Research • Nov 13, 2026

Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 27.7%: Read This Before Placing a Bet
The consensus price target hints at a 27.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • Nov 12, 2026

Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research • Nov 12, 2026

Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the Company will be featured on Health Uncensored with Dr. Drew in a segment titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer.” The segment is scheduled to air nationally on Sunday, November 15, 2026. A podcast is also expected to be released following the television broadcast.
Business Wire • Nov 11, 2026

Delcath Systems Q3 Earnings Call Highlights
Delcath Systems NASDAQ: DCTH reported record third-quarter revenue of $35.1 million, up 71% from a year earlier, as use of its HEPZATO KIT increased across U.S. treatment centers. The company also raised its full-year revenue outlook and reported higher net income and positive operating cash flow.
MarketBeat • Nov 9, 2026

Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 9, 2026

Delcath Systems Reports Third Quarter 2026 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Total revenue of $35.1 million, compared with $20.6 million in the third quarter of 2025 HEPZATO KIT™ revenue of $32.7 million, compared to $19.3 million in the third quarter of 2025.
Business Wire • Nov 9, 2026

Delcath Systems, Inc. (DCTH) Q3 Earnings and Revenues Top Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to earnings of $0.02 per share a year ago.
Zacks Investment Research • Nov 9, 2026

Delcath Systems: Intriguingly Poised Ahead Of Q3 Earnings
Delcath Systems, which has outperformed other Russell 2000 stocks and healthcare equipment makers by 3x and 8x this year, is due to publish Q3 results on the 9th of Nov. The probability of a topline beat looks high, while a beat over 5% could be taken well; GMs may see a sequential dip but will rebound in Q4. Recent CHOPIN phase II trial success and expansion of active treatment centers enhance DCTH's growth prospects, with 24% topline growth expected in the medium term.
Seeking Alpha • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Delcath Systems Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.